Form 4: Aptevo Director Granted 7,200 RSUs

Aptevo Therapeutics Inc. director John Niederhuber was granted 7,200 Restricted Stock Units, vesting one year from the August 6, 2025 grant date.

Summary

• John Niederhuber, a director of Aptevo Therapeutics Inc. (APVO), was granted 7,200 Restricted Stock Units (RSUs).
• These RSUs convert into common stock on a one-for-one basis.
• The RSUs are scheduled to vest in full on the first anniversary of the grant date, which is August 6, 2025.
• Following this transaction, John Niederhuber beneficially owns 7,200 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a standard compensation practice that aligns the director's interests with shareholders. It is not a significant event that would drastically alter the company's financial standing or strategic direction, but it indicates ongoing board activity and compensation.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
• This type of equity compensation is a common practice for retaining and incentivizing key personnel, including board members.

Future Outlook

NA

Industry Context

This RSU grant is a standard form of equity compensation for directors in the biotechnology and pharmaceutical industries, aiming to align director incentives with long-term shareholder value creation. It reflects common practices for attracting and retaining experienced board members.

Comparison to Industry Standards

• The grant of 7,200 RSUs to a director is a typical component of non-executive director compensation packages in the biotech sector.
• Similar grants are observed at companies like Xencor (XNCR) or MacroGenics (MGNX) where directors receive annual equity awards as part of their compensation for board service.
• The specific number of units would need to be benchmarked against Aptevo's market capitalization and peer group compensation data to assess if it's above, below, or in line with industry averages, but the mechanism itself is standard.

Related Party Transactions

• The grant of Restricted Stock Units to John Niederhuber, a director, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by tying compensation to stock performance. It could lead to minor dilution upon vesting, but this is typically factored into compensation plans.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The 7,200 Restricted Stock Units are scheduled to vest in full on August 6, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice. It does not contain information that would significantly alter the investment thesis for Aptevo Therapeutics Inc. Therefore, a "hold" recommendation is appropriate, as the filing itself does not provide new fundamental data to warrant a change in investment stance.

Keywords

Aptevo Therapeutics, APVO, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, SEC Form 4, John Niederhuber